Japan’s health ministry on July 13 announced its first purchase agreement for the government stockpiling of Shionogi’s anti-flu drug Xofluza (baloxavir marboxil), which secures enough doses to cover 1,435,000 people.The ministry also said that it also concluded a purchase agreement…
To read the full story
Related Article
- Govt Panel Agrees to Add Xofluza to Flu Drug Stockpile
June 22, 2022
REGULATORY
- Japan Sets Up Radiopharma Discovery Hub in Fukushima, Targets Rare Cancers
March 18, 2026
- MHLW Seeks Industry Survey on Petroleum-Linked Products amid Iran Crisis
March 18, 2026
- MHLW Orders Label Revisions for Antiepileptics and Other Drugs
March 18, 2026
- MHLW Panel OKs Draft Criteria for “Specified Medical Technologies”
March 17, 2026
- Growth Strategy Council WG Weighs Incentives for Clinical Trial Sites
March 17, 2026
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…





